BiondVax Issues Clarification Regarding Third Quarter 2018 Financial Results
JERUSALEM, Nov. 19, 2018
JERUSALEM, Nov. 19, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), a Phase 3 clinical stage biopharmaceutical company focused on developing and commercializing M-001, a universal flu vaccine candidate, today issued a clarification regarding information published on November 13, 2018 in connection with the third quarter financial results.
As correctly indicated in the financial tables filed on November 14, 2018 in a 6-K with the United States Securities And Exchange Commission (SEC), third quarter operating expenses were NIS 5.8m (US$1.6m), while cumulative operating expenses for the nine months ending September 30, 2018 were NIS 49.1m (US$13.5m). As well, third quarter R&D expenses amounted to NIS 4.3m (US$1.2m), while cumulative R&D expenses for the nine months ending September 30, 2018 were NIS 45.3m (US$12.5m).
Note that results are in New Israel Shekels (NIS) and the convenience translation to $US is provided using the exchange rate of 3.627 (NIS/$US) as at September 30, 2018.
BiondVax (NASDAQ: BVXV) is a Phase 3 clinical stage biopharmaceutical company developing a universal flu vaccine. The vaccine candidate, called M-001, is designed to provide multi-season protection against current and future, seasonal and pandemic influenza virus strains. BiondVax's proprietary technology utilizes a unique combination of conserved and common influenza virus peptides, activating both arms of the immune system for a cross-protecting and long-lasting effect. In a total of 6 completed Phase 1/2 and Phase 2 human clinical trials, covering 698 participants, the vaccine has been shown to be safe, well-tolerated, and immunogenic. Please visit www.biondvax.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of BiondVax Pharmaceuticals Ltd. Risks and uncertainties include, but are not limited to, the prosecution and outcome of the ongoing Phase 2 and Phase 3 trials and any subsequent trials; timing of receipt of regulatory approval of the new manufacturing facility its products; ability to demonstrate the efficacy and safety of the vaccine; the timing of clinical trials and marketing approvals; the risk that drug development involves a lengthy and expensive process with uncertain outcome; the ability of the Company to maintain, preserve and defend its intellectual property and patents granted; whether our vaccine candidate will successfully advance through the clinical trial process on a timely basis, or at all, and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; the adequacy of available cash resources and the ability to raise capital when needed. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2017 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov, and in the Company's periodic filings with the SEC. We undertake no obligation to revise or update any forward-looking statement for any reason.
Contact Details: Joshua E.Phillipson , +972-8-930-2529, email@example.com
SOURCE BiondVax Pharmaceuticals Ltd.